Switching Weight Loss Medications: Mounjaro to Wegovy Dose Guide

10 / Jun

You wake up one morning and wonder whether the medication you have been taking for months is really giving you the best possible results. Maybe your weight loss has plateaued, your tolerance has changed, or your prescriber has suggested it might be worth exploring an alternative. For many people across Manchester and beyond, that moment raises a very specific question: what does switching between Mounjaro and Wegovy actually involve, and how do the doses compare?

At Everest Pharmacy, we support patients through every stage of their weight loss journey, including decisions about switching medications. This guide covers the key differences between Mounjaro and Wegovy dosing, explains why a direct dose conversion is more complicated than it sounds, and gives you the practical information you need to have an informed conversation with your healthcare provider.

If you are currently on either medication and thinking about switching, get in touch with our team or book a consultation at Everest Pharmacy to talk through your options.

Book Now

For those exploring clinically supervised options, Mounjaro and Wegovy are both available through Everslim, our sister clinic offering prescription weight loss treatment led by UK pharmacists and independent prescribers. All treatments are assessed and dispensed under full clinical supervision, with support built in at every stage of the journey.

Mounjaro and Wegovy at a Glance

Quick Overview

Mounjaro (tirzepatide) is a dual GIP and GLP-1 receptor agonist. It activates two separate hormone pathways involved in appetite regulation and blood sugar control.
Wegovy (semaglutide) is a GLP-1 receptor agonist only. It works on one of the same pathways as Mounjaro but does not activate the GIP receptor.
Both are administered as weekly subcutaneous injections.
Both follow a gradual dose escalation schedule to minimise side effects such as nausea, vomiting, and gastrointestinal discomfort.
Clinical trials suggest that Mounjaro may produce greater average weight loss at its highest doses in adults without type 2 diabetes, though individual responses vary significantly.
Neither medication is interchangeable with the other in a straightforward way, and switching requires careful clinical judgement.

Why Do People Switch Between Mounjaro and Wegovy?

There are several reasons why a patient or prescriber might consider switching from one medication to the other. Understanding the motivation behind the switch can help inform how the transition is managed.

Common reasons for switching from Mounjaro to Wegovy include:

- Availability or supply issues with Mounjaro at a particular dose
- Side effect profile that feels more manageable on semaglutide
- Cost or insurance coverage differences
- A prescriber preferring semaglutide for a particular patient’s clinical profile

Common reasons for switching from Wegovy to Mounjaro include:

Plateauing weight loss despite reaching the highest Wegovy dose
A desire to explore the dual-action mechanism of tirzepatide
Clinical evidence suggesting tirzepatide may offer greater efficacy at higher doses
Patient preference or prescriber recommendation following a review

Can You Directly Compare the Doses?

This is one of the most important points in this entire guide. Mounjaro and Wegovy are not directly comparable on a milligram-for-milligram basis. They are different molecules, work through different mechanisms, and their dose escalation schedules are structured independently of one another.

There is no universally agreed conversion chart that says a specific dose of Mounjaro is equivalent to a specific dose of Wegovy. What exists instead is clinical reasoning: prescribers consider how long a patient has been on their current medication, what dose they have reached, how well they have tolerated it, and what the goals of the switch are.

That said, some broad comparisons can be made based on mechanism, tolerability, and clinical trial data. The table below reflects approximate clinical context rather than a direct pharmacological conversion.

Mounjaro Dose (Tirzepatide)	Approximate Clinical Context	Closest Wegovy Dose (Semaglutide)	Notes
2.5mg (starting dose)	Initiation / tolerance building	0.25mg (starting dose)	Both are starter doses; neither is a therapeutic maintenance dose
5mg	Early escalation	0.5mg	Tolerability being established on both
7.5mg	Mid escalation	1mg	Some patients see early weight loss response here
10mg	Mid to upper range	1.7mg	Weight loss effects becoming more established
12.5mg	Upper escalation	2.4mg (standard maintenance)	Mounjaro’s upper doses often outperform Wegovy’s maximum in trials
15mg (maximum)	Maximum licensed dose	2.4mg or 7.2mg (newly approved)	No direct equivalent; clinical goals should guide the decision

Please note: this table is for informational context only and does not constitute medical advice. Always consult a qualified healthcare professional before switching or adjusting any weight loss medication.

Dose-by-Dose Comparison: Understanding Each Step

Starting Doses: Mounjaro 2.5mg vs Wegovy 0.25mg

Both medications begin at their lowest available dose. These starting doses are not intended to produce significant weight loss on their own. They exist to help the body adjust to the medication and reduce the severity of early side effects. If switching between the two, most prescribers would recommend starting again at or near the initiation dose on the new medication, regardless of how long you have been on the original drug.

Early Escalation: Mounjaro 5mg vs Wegovy 0.5mg

At this stage, patients are typically finding their tolerance. Both medications carry a risk of nausea and digestive discomfort during dose escalation. Switching at this point would likely mean stepping back to a lower dose on the new medication to allow the body to adapt, even if you have tolerated the original medication well.

Mid Range: Mounjaro 7.5mg and 10mg vs Wegovy 1mg and 1.7mg

This is where some of the most meaningful weight loss tends to begin for many patients. Both medications show stronger efficacy as the dose increases, though they achieve this through different pathways. Switching here requires careful consideration because the mechanisms are different enough that your previous tolerance at a mid-range Mounjaro dose does not guarantee an equivalent tolerance to a mid-range Wegovy dose.

Upper Doses: Mounjaro 12.5mg and 15mg vs Wegovy 2.4mg (and 7.2mg)

At the upper end of the dose ranges, the differences between the two medications become more clinically significant. The SURMOUNT trials showed that tirzepatide at 15mg produced average weight loss of around 20 to 22 percent of body weight. Semaglutide at 2.4mg has shown average losses of around 15 percent in the STEP trials. This does not mean Wegovy is ineffective, but it does mean that switching from the highest Mounjaro dose to Wegovy’s standard maximum may feel like a step back for some patients.

The Newly Approved Wegovy 7.2mg: What You Need to Know

In a significant development for weight management, the UK government approved a single-dose 7.2mg semaglutide Wegovy pen for adult patients with obesity. This is a higher-strength formulation designed as a single-use injection pen, separate from the standard weekly dose escalation schedule used in the existing Wegovy product.

Key points about the 7.2mg approval:

- It is approved for adult patients with obesity and represents an alternative delivery option within the semaglutide class
- The 7.2mg dose is significantly higher than the standard 2.4mg weekly maintenance dose
- This development may change how prescribers approach switching decisions, particularly for patients who have plateaued on standard Wegovy dosing
- Availability and prescribing pathways for the 7.2mg pen are still developing, and clinical guidance is continuing to evolve
- Patients should not attempt to access or use this formulation without clear prescriber oversight and assessment

For patients who were considering switching from Wegovy to Mounjaro due to reaching the ceiling of standard semaglutide dosing, the 7.2mg approval adds a new option worth discussing with your prescriber.

Switching in Either Direction: What to Expect

Whether you are moving from Mounjaro to Wegovy or the reverse, the transition process typically follows similar principles.

- You will almost always need to restart at a lower dose on the new medication
- Your prescriber may recommend a washout period or a staggered transition depending on your current dose and clinical situation
- Side effects may return or worsen temporarily as your body adapts to the new drug
- Weight loss progress may slow during the transition period before stabilising
- Regular follow-up and monitoring is important to assess how well the new medication is working

Switching should never be self-managed. A prescriber who understands your full medical history and weight loss goals is best placed to guide the decision and the dose restart.

How We Help You Decide if Switching Is Right for You

At Everest Pharmacy in Manchester, we work with patients at every stage of their weight management journey. Our team can support you by helping you understand the clinical differences between Mounjaro and Wegovy, reviewing your current progress and tolerance, discussing the implications of switching in either direction, and signposting you to appropriate prescribing support where needed.

We believe that good decisions come from good information. If you are feeling uncertain about whether to switch, or simply want to talk through what the options mean for your situation, we are here.

Book an appointment with Everest Pharmacy today, or contact us to speak to a member of our team in Manchester or Sheffield.

Why Choose Everslim for Weight Loss Treatment?

Everslim is a GPhC-regulated online weight loss clinic staffed by UK-qualified pharmacists and independent prescribing clinicians. Whether injectable treatment is right for you or you are better suited to an oral option such as Orlistat, our clinical team at Everslim will assess your individual circumstances before any prescription is issued.

Patients choosing our sister services benefit from:

A thorough online consultation reviewed by a qualified prescriber
Medication dispensed from a UK-regulated pharmacy and delivered to your door
Ongoing dose reviews and clinical support throughout treatment
Transparent pricing with no hidden charges
Access to a clinical team if questions or concerns arise between doses

Frequently Asked Questions

If I have been on Mounjaro for a year, do I still need to restart Wegovy from the lowest dose?

In most cases, yes. Even if you have been on a high Mounjaro dose for a long time and tolerated it well, your body has not been exposed to semaglutide. The two medications are pharmacologically distinct, which means your GI tolerance and physiological response to Wegovy cannot be assumed based on your Mounjaro history. Most prescribers will start you at the lowest Wegovy dose and escalate carefully.

Will I regain weight during the switch between medications?

There is a possibility of some weight regain or stalled progress during a transition, particularly if there is a gap between stopping one medication and starting another, or if you spend several weeks on a lower introductory dose of the new drug. This is generally temporary, but it is worth discussing with your prescriber so you have realistic expectations going into the switch.

Is there any clinical guidance on which dose of Wegovy to start at if I was on Mounjaro 10mg?

There is no universally agreed starting protocol for this specific scenario. Clinical decisions vary between prescribers and are influenced by your individual response, medical history, and the reason for switching. Some prescribers may choose to start at 0.5mg or 1mg rather than the very lowest 0.25mg dose if you have demonstrated a strong tolerability history, but this is entirely at their discretion and should not be assumed.

Can I take Mounjaro and Wegovy at the same time to ease the transition?

No. These medications should never be taken simultaneously. Both act on overlapping hormone pathways and combining them would carry a serious risk of severe side effects including dangerously low blood sugar, excessive nausea and vomiting, and cardiovascular complications. Any transition between the two must be managed with one medication being stopped before the other is started.

How does the new Wegovy 7.2mg pen differ from the standard weekly injections?

The newly approved 7.2mg semaglutide pen is a different formulation to the standard weekly Wegovy maintenance dose of 2.4mg. It is a single-dose pen approved for adult patients with obesity. The clinical context in which it will be prescribed, including whether it is used as a continuation of standard therapy or as an alternative pathway, is still being established. It should only ever be used under direct prescriber supervision and is not a self-managed upgrade from the standard regimen.

Does switching medications reset my eligibility for weight loss programmes or NHS support?

This depends on the specific programme or pathway you are enrolled in. Some NHS or private weight management services tie eligibility and monitoring to a specific medication. Switching could affect your position within that pathway. It is worth checking with both your prescriber and the service managing your programme before making any change, to avoid unintentionally losing access to support you are currently receiving.

Personalised Weight Loss Support in Manchester and Sheffield

Switching weight loss medications is not a decision to make lightly, and it is certainly not one to make alone. Mounjaro and Wegovy are both effective, clinically validated options, but they work differently, escalate differently, and suit different patients at different stages of their journey. A dose that feels equivalent on paper may feel very different in practice.

If you are in Manchester or Sheffield and want professional, honest guidance about whether switching is the right move for you, the team at Everest Pharmacy is ready to help. We take the time to understand your individual situation and give you the information you need to make a confident, well-supported decision.

Book your appointment with Everest Pharmacy today and take the next step in your weight loss journey with a team that genuinely has your health at the centre of everything we do.

Book Now

☑ Clinically Reviewed by Pharmacy Mentor

A pharmacist reviews the content to help ensure medicines are presented responsibly and that patient facing health information is accurate, appropriate, and aligned with current clinical guidance.

Last reviewed: 10 June 2026

Written on behalf of Everest Pharmacy by Pharmacy Mentor.